Assertio Holdings, Inc. ASRT
We take great care to ensure that the data presented and summarized in this overview for Assertio Holdings, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding ASRT
View all-
Nantahala Capital Management, LLC New Canaan, CT9.27MShares$9.46 Million0.57% of portfolio
-
Black Rock Inc. New York, NY6.35MShares$6.48 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.92MShares$5.02 Million0.0% of portfolio
-
Aqr Capital Management LLC Greenwich, CT3.23MShares$3.3 Million0.01% of portfolio
-
Russell Investments Group, Ltd.2.35MShares$2.39 Million0.0% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny2.09MShares$2.13 Million0.0% of portfolio
-
Geode Capital Management, LLC Boston, MA2.05MShares$2.09 Million0.0% of portfolio
-
Cowen And Company, LLC1.58MShares$1.62 Million0.05% of portfolio
-
State Street Corp Boston, MA1.53MShares$1.56 Million0.0% of portfolio
-
David A. Siegel Two Sigma Advisers, LP | New York, Ny1.13MShares$1.15 Million0.0% of portfolio
Latest Institutional Activity in ASRT
Top Purchases
Top Sells
About ASRT
Assertio Holdings, Inc., a specialty pharmaceutical company, provides medicines in the areas of neurology, hospital, and pain and inflammation. Its pharmaceutical products include INDOCIN, an oral solution and a suppository form for the treatment of moderate to severe rheumatoid arthritis, including acute flares of chronic disease; ankylosing spondylitis and osteoarthritis; and acute painful shoulder and gouty arthritis. It also provides CAMBIA, a non-steroidal anti-inflammatory drug (NSAID) for the treatment of migraine, nausea, photophobia, and phonophobia; Zipsor, a NSAID for relief of mild to moderate acute pain; SPRIX, a NSAID for the short term management of moderate to moderately severe pain that requires analgesia at the opioid level; and Otrexup, a single-dose auto-injector containing a prescription medicine and methotrexate that is used to treat adults with severe, active rheumatoid arthritis, and children with active polyarticular juvenile idiopathic arthritis. The company was formerly known as Assertio Therapeutics, Inc. and changed its name to Assertio Holdings, Inc. in May 2020. Assertio Holdings, Inc. was incorporated in 1995 and is headquartered in Lake Forest, Illinois.
Insider Transactions at ASRT
Insider Transaction List
View allDate | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
---|---|---|---|---|---|
May 12
2024
|
Ajay Patel SVP and CFO |
SELL
Payment of exercise price or tax liability
|
Direct |
16,840
-9.83%
|
$0
$0.96 P/Share
|
May 12
2024
|
Ajay Patel SVP and CFO |
BUY
Exercise of conversion of derivative security
|
Direct |
38,017
+18.16%
|
-
|
May 12
2024
|
Paul Schwichtenberg SVP, CCO |
SELL
Payment of exercise price or tax liability
|
Direct |
16,840
-11.86%
|
$0
$0.96 P/Share
|
May 12
2024
|
Paul Schwichtenberg SVP, CCO |
BUY
Exercise of conversion of derivative security
|
Direct |
38,017
+21.13%
|
-
|
May 12
2024
|
Sam Schlessinger SVP, General Counsel |
SELL
Payment of exercise price or tax liability
|
Direct |
16,840
-12.12%
|
$0
$0.96 P/Share
|
May 12
2024
|
Sam Schlessinger SVP, General Counsel |
BUY
Exercise of conversion of derivative security
|
Direct |
38,017
+21.49%
|
-
|
Mar 14
2024
|
James L Tyree Director |
SELL
Open market or private sale
|
Direct |
10,251
-5.16%
|
$10,251
$1.12 P/Share
|
Feb 21
2024
|
Paul Schwichtenberg SVP, CCO |
SELL
Payment of exercise price or tax liability
|
Direct |
8,506
-7.57%
|
$0
$0.79 P/Share
|
Feb 21
2024
|
Paul Schwichtenberg SVP, CCO |
BUY
Exercise of conversion of derivative security
|
Direct |
17,151
+13.24%
|
-
|
Feb 21
2024
|
Sam Schlessinger SVP, General Counsel |
SELL
Payment of exercise price or tax liability
|
Direct |
8,506
-7.78%
|
$0
$0.79 P/Share
|
Feb 21
2024
|
Sam Schlessinger SVP, General Counsel |
BUY
Exercise of conversion of derivative security
|
Direct |
17,151
+13.55%
|
-
|
Feb 21
2024
|
Ajay Patel SVP and CFO |
SELL
Payment of exercise price or tax liability
|
Direct |
8,506
-6.0%
|
$0
$0.79 P/Share
|
Feb 21
2024
|
Ajay Patel SVP and CFO |
BUY
Exercise of conversion of derivative security
|
Direct |
17,151
+10.79%
|
-
|
Feb 11
2024
|
Ajay Patel SVP and CFO |
SELL
Payment of exercise price or tax liability
|
Direct |
16,382
-11.62%
|
$0
$0.8 P/Share
|
Feb 11
2024
|
Ajay Patel SVP and CFO |
BUY
Exercise of conversion of derivative security
|
Direct |
47,348
+25.14%
|
-
|
Feb 11
2024
|
Paul Schwichtenberg SVP, CCO |
SELL
Payment of exercise price or tax liability
|
Direct |
16,382
-14.67%
|
$0
$0.8 P/Share
|
Feb 11
2024
|
Paul Schwichtenberg SVP, CCO |
BUY
Exercise of conversion of derivative security
|
Direct |
47,348
+29.78%
|
-
|
Feb 11
2024
|
Sam Schlessinger SVP, General Counsel |
SELL
Payment of exercise price or tax liability
|
Direct |
6,552
-6.63%
|
$0
$0.8 P/Share
|
Feb 11
2024
|
Sam Schlessinger SVP, General Counsel |
BUY
Exercise of conversion of derivative security
|
Direct |
18,939
+16.09%
|
-
|
Nov 14
2023
|
Sravan Kumar Emany Director |
BUY
Grant, award, or other acquisition
|
Direct |
177,570
+50.0%
|
-
|
Last 12 Months Summary
Exercise of conversion of derivative security | 306K shares |
---|---|
Grant, award, or other acquisition | 265K shares |
Open market or private sale | 494K shares |
---|---|
Payment of exercise price or tax liability | 127K shares |